Paid Clinical Trials Fayetteville
Discover 185 paid clinical trials in Fayetteville, Arkansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsTesting the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04530565
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Blinatumomab
Bone Marrow Aspiration and Biopsy
Cyclophosphamide
Cytarabine
Bupropion to Reduce Cancer Related Fatigue in Cancer SurvivorsBupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Sponsor:
University of Rochester NCORP Research Base
Location:
Code:
NCT03996265
Conditions
Be Diagnosed With Cancer and Have Completed Systemic Therapy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bupropion Hydrochloride Controlled-release
Placebo Administration
Quality-of-Life Assessment
Questionnaire Administration
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Sponsor:
Incyte Corporation
Location:
Code:
NCT06516965
Conditions
Prurigo Nodularis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Povorcitinib
Placebo
Study of LP-184 in Patients with Advanced Solid TumorsStudy of LP-184 in Patients with Advanced Solid Tumors
Sponsor:
Lantern Pharma Inc.
Location:
Code:
NCT05933265
Conditions
Advanced Solid Tumor
Metastatic Solid Tumor
GBM
TNBC - Triple-Negative Breast Cancer
NSCLC
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
LP-184
Spironolactone
Olaparib
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISCA Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Sponsor:
Target PharmaSolutions, Inc.
Location:
Code:
NCT03661866
Conditions
Atopic Dermatitis
Alopecia Areata
Hidradenitis Suppurativa
Vitiligo
Psoriasis
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
MFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaMFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Sponsor:
Alliance for Clinical Trials in Oncology
Location:
Code:
NCT05677490
Conditions
Advanced Esophageal Adenocarcinoma
Advanced Gastric Adenocarcinoma
Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage III Esophageal Adenocarcinoma AJCC V8
Clinical Stage III Gastric Cancer AJCC V8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Fluorouracil
Leucovorin Calcium
Oxaliplatin
Irinotecan
Nivolumab
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Sponsor:
AstraZeneca
Location:
Code:
NCT06103864
Conditions
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Dato-DXd
Durvalumab
Paclitaxel
Nab-paclitaxel
Gemcitabine
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through RandomizationJAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Sponsor:
Endologix
Location:
Code:
NCT05064540
Conditions
AAA
AAA - Abdominal Aortic Aneurysm
Eligibility Criteria
Sex: All
Age: 21+
Healthy Volunteers: Not accepted
Interventions
Alto Abdominal Stent Graft System
FDA Approved EVAR AAA Graft Systems
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialChemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT06096844
Conditions
Advanced Lung Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 70+
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Computed Tomography
Magnetic Resonance Imaging
Nab-paclitaxel
Paclitaxel